Skip to content
sellWeak cluster of 210b5-1 plan

James Mulay sold $1.8M of CGON

director at CG Oncology, Inc.. 24,165 shares at an average of $75.16, traded Jul 10, 2026, filed Jul 14, 2026.

Warning score
33
Value
$1.8M
24,165 shares
Holdings after
0
-100% from before
From 52-week low
+214%
low $23.94, close $75.24
From 52-week high
0%
high $75.24, as of Jul 10, 2026

Score components

  • Role
    Director
    +15
  • Trade size
    $1.8M at market
    +25
  • Share of holdings sold
    Sold 100% of holdings
    +20
  • Cluster
    2 insiders selling within 14 days
    +8
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

CGONOct 9, 2026 · close 63.82
Since filing Jul 14, 2026: -11.1%SPY +3.7% · excess -14.8%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001193125-26-303188, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Jul 10, 2026MOption exercise
Common Stock10b5-1
+24,165$26.63$644k24,165Jul 14, 2026
Jul 10, 2026SOpen-market sale
Common Stock10b5-1
-24,165$75.16$1.8M0Jul 14, 2026
Jul 10, 2026MOption exercise
Director Stock Option (right to buy)derivative10b5-1
-24,165$0.00$00Jul 14, 2026

Related signals

Other insiders at CG Oncology, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
8Weak
CGONsell10b5-1
CG Oncology, Inc.
Leonard E Post
director
$73k
1,000 shares
-100%
8Weak
CGONsell10b5-1
CG Oncology, Inc.
Leonard E Post
director
$75k
1,000 shares
-100%
16Weak
CGONsell 210b5-1
CG Oncology, Inc.
Leonard E Post
director
$71k
1,000 shares
-100%
31Weak
CGONbuy10b5-1
CG Oncology, Inc.
Brian Guan-Chyun Liu
director
$25M
371,085 shares
+24%
23Weak
CGONsell 210b5-1
CG Oncology, Inc.
Leonard E Post
director
$350k
5,000 shares
-100%
22Weak
CGONsell 210b5-1
CG Oncology, Inc.
Leonard E Post
director
$325k
5,000 shares
-100%
18Weak
CGONsell 210b5-1
CG Oncology, Inc.
James Mulay
director
$118k
1,964 shares
-300%
15Weak
CGONsell 210b5-1
CG Oncology, Inc.
Leonard E Post
director
$55k
1,000 shares
-100%
25Weak
CGONsell10b5-1
CG Oncology, Inc.
James Mulay
director
$1.1M
15,600 shares
-100%
10Weak
CGONsell10b5-1
CG Oncology, Inc.
James Mulay
director
$125k
1,964 shares
-300%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

James Mulay sold $1.8M of CGON | InsiderTell